Genetic and Nongenetic Determinants of Variable Warfarin Dose Requirements: A Report from North India
Public Health Genomics · 2022 · 25 (1-2) · 52-60
DOI: 10.1159/000519462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Public Health Genomics, online erschienen am 21.10.2021. Verfasst von Navjot Kaur und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, VMMC & Safdarjung Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Warfarin, Cytochrome P-450 CYP2C9, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Warfarin is widely used and will continue to be prescribed especially in developing countries due to its low cost. Given the huge patient load requiring anticoagulation, there is a need to develop strategies to optimize warfarin therapy for ensuring safe and effective anticoagulation. In the present work, we aimed at elucidating the association of genetic and nongenetic variables with warfarin dose requirement in patients attending the cardiovascular clinic in a tertiary care center of North India.
Methods
This was a prospective study conducted over 1 year. Patient demographic and clinical details were captured in customized case record forms. Genotyping was done using the polymerase chain reaction-restriction fragment length polymorphism method. Pharmacogenetic influence of CYP2C9 (rs1799853 and rs1057910) and VKORC1 (rs9923231) variant alleles was studied. The association of genetic and nongenetic factors with warfarin dose was quantified using a stepwise multivariate linear regression model.
Results
Two hundred and forty patients were screened. Data from 82 eligible patients were used for quantifying the association of genetic and nongenetic factors with warfarin dose. A descriptive model based on CYP2C9*3 (rs1057910) and VKORC1 (rs9923231) variant alleles and BMI was developed. The model explains nearly half of the interindividual variation in warfarin dose requirement.
Conclusion
The model explains nearly half of the interindividual variation in warfarin dose in patients with atrial fibrillation and or requiring valve replacement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, VMMC & Safdarjung Hospital, New Delhi, India.
- Clinical Pharmacology Resident, Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, nusrat.shafiq.pgi@gmail.com.
- Department of Cardiology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Hematology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Zitieren
APA
Kaur, N., Pandey, A., Shafiq, N., Gupta, A., Das, R., Singh, H., Ahluwalia, J., & Malhotra, S. (2022). Genetic and Nongenetic Determinants of Variable Warfarin Dose Requirements: A Report from North India. Public Health Genomics, 25(1-2), 52-60. https://doi.org/10.1159/000519462
Vancouver
Kaur N, Pandey A, Shafiq N, Gupta A, Das R, Singh H, et al. Genetic and Nongenetic Determinants of Variable Warfarin Dose Requirements: A Report from North India. Public Health Genomics. 2022;25(1-2):52-60. doi:10.1159/000519462
BibTeX
@article{Kaur2022,
author = {Kaur, Navjot and Pandey, Avaneesh and Shafiq, Nusrat and Gupta, Ankur and Das, Reena and Singh, Harkant and Ahluwalia, Jasmina and Malhotra, Samir},
title = {Genetic and Nongenetic Determinants of Variable Warfarin Dose Requirements: A Report from North India},
journal = {Public Health Genomics},
year = {2022},
volume = {25},
number = {1-2},
pages = {52--60},
doi = {10.1159/000519462}
}
EUVIMED